RxDoctor Payments DataLook up a doctor →

Richard Nowak, MD

Neurology · New Haven, CTNPI 1730346818

Payments from drug & device makers

$1,015,329in general payments, 2019–2025

Across 227 payments — averaging $4472.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$412K
  • Amgen$242K
  • AstraZeneca$128K
  • Janssen Research & Development, LLC$125K
  • UCB Biosciences Inc.$44K
  • Argenx US, Inc.$22K
  • plus $44K from 9 others
$13,081in research payments, 2019–2025

Across 6 payments — averaging $2180.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$10K
  • Novartis Pharma AG$2K
  • AstraZeneca$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,015,329 in reported general payments places this provider in the 95th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Medicare billing

Part B allowed, 2024
$37,780
Medicare patients
127
Services billed
274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →